Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis

J. Salazar, D. Pirela, M. Nava, A. Castro, L. Angarita, H. Parra, S. Durán-Agüero, DM. Rojas-Gómez, N. Galbán, R. Añez, M. Chacín, A. Diaz, N. Villasmil, JB. De Sanctis, V. Bermúdez

. 2022 ; 23 (6) : . [pub] 20220315

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019184

Grantová podpora
CC-0437-10-21-09-10 Consejo de Desarrollo Científico, Humanístico y Tecnológico (CONDES), University of Zulia

Cardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019184
003      
CZ-PrNML
005      
20220804135420.0
007      
ta
008      
220720s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms23063133 $2 doi
035    __
$a (PubMed)35328553
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Salazar, Juan $u Endocrine and Metabolic Diseases Research Center "DR. Felix Gomez", School of Medicine, University of Zulia, Maracaibo 4001, Venezuela $1 https://orcid.org/000000034211528X
245    10
$a Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis / $c J. Salazar, D. Pirela, M. Nava, A. Castro, L. Angarita, H. Parra, S. Durán-Agüero, DM. Rojas-Gómez, N. Galbán, R. Añez, M. Chacín, A. Diaz, N. Villasmil, JB. De Sanctis, V. Bermúdez
520    9_
$a Cardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD.
650    _2
$a zvířata $7 D000818
650    12
$a ateroskleróza $x metabolismus $7 D050197
650    12
$a kardiovaskulární nemoci $x farmakoterapie $7 D002318
650    _2
$a kyseliny dokosahexaenové $x metabolismus $x farmakologie $x terapeutické užití $7 D004281
650    12
$a omega-3 mastné kyseliny $x metabolismus $x farmakologie $x terapeutické užití $7 D015525
650    _2
$a lidé $7 D006801
650    _2
$a zánět $x metabolismus $7 D007249
650    _2
$a mediátory zánětu $x metabolismus $7 D018836
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Pirela, Daniela $u Endocrine and Metabolic Diseases Research Center "DR. Felix Gomez", School of Medicine, University of Zulia, Maracaibo 4001, Venezuela
700    1_
$a Nava, Manuel $u Endocrine and Metabolic Diseases Research Center "DR. Felix Gomez", School of Medicine, University of Zulia, Maracaibo 4001, Venezuela $1 https://orcid.org/0000000197691693
700    1_
$a Castro, Ana $u Endocrine and Metabolic Diseases Research Center "DR. Felix Gomez", School of Medicine, University of Zulia, Maracaibo 4001, Venezuela
700    1_
$a Angarita, Lissé $u Escuela de Nutrición y Dietética, Facultad de Medicina, Universidad Andres Bello, Concepción 4260000, Chile $1 https://orcid.org/0000000178605112
700    1_
$a Parra, Heliana $u Endocrine and Metabolic Diseases Research Center "DR. Felix Gomez", School of Medicine, University of Zulia, Maracaibo 4001, Venezuela $1 https://orcid.org/0000000266044212
700    1_
$a Durán-Agüero, Samuel $u Facultad de Ciencias para el Cuidado de la Salud, Universidad de San Sebastián, Lota 2465, Providencia, Santiago 7500000, Chile $1 https://orcid.org/0000000205483676
700    1_
$a Rojas-Gómez, Diana Marcela $u Escuela de Nutrición y Dietética, Facultad de Medicina, Universidad Andres Bello, Santiago 8370321, Chile $1 https://orcid.org/0000000269566315
700    1_
$a Galbán, Néstor $u Endocrine and Metabolic Diseases Research Center "DR. Felix Gomez", School of Medicine, University of Zulia, Maracaibo 4001, Venezuela
700    1_
$a Añez, Roberto $u Departamento de Endocrinología y Nutrición, Hospital General Universitario Gregorio Marañón, 28009 Madrid, Spain
700    1_
$a Chacín, Maricarmen $u Facultad de Ciencias de la Salud, Universidad Simón Bolívar, Barranquilla 080002, Colombia
700    1_
$a Diaz, Andrea $u Endocrine and Metabolic Diseases Research Center "DR. Felix Gomez", School of Medicine, University of Zulia, Maracaibo 4001, Venezuela
700    1_
$a Villasmil, Nelson $u Endocrine and Metabolic Diseases Research Center "DR. Felix Gomez", School of Medicine, University of Zulia, Maracaibo 4001, Venezuela $1 https://orcid.org/0000000272274866
700    1_
$a De Sanctis, Juan Bautista $u Institute of Molecular and Translational Medicine, Czech Advanced Technology and Research Institute, Palacký University, Hněvotínská 1333/5, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000254804608
700    1_
$a Bermúdez, Valmore $u Facultad de Ciencias de la Salud, Universidad Simón Bolívar, Barranquilla 080002, Colombia $1 https://orcid.org/0000000318808887
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 23, č. 6 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35328553 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135414 $b ABA008
999    __
$a ok $b bmc $g 1822679 $s 1170427
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 23 $c 6 $e 20220315 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a CC-0437-10-21-09-10 $p Consejo de Desarrollo Científico, Humanístico y Tecnológico (CONDES), University of Zulia
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace